Poster Abstracts • OFID 2017:4 (Suppl 1) • 661 patients are treated for HCV infection. This study aims to describe barriers to hepatitis C treatment in HIV/HCV co-infected patients.
Background. Direct acting antiretrovirals in clinical trials have high efficacy achieving sustained virologic response (SVR) in Hepatitis C virus (HCV) and human-immunodeficiency virus (HIV) co-infected patients. We aim to investigate real-world HCV SVR outcome of ledipasvir/sofosbuvir therapy in the HIV population.
Methods. We performed a retrospective chart review from 2014 to 2016 of patients with HCV/HIV coinfection who received ledipasvir/sofosbuvir in a freestanding HIV clinic. Demographic data collected includes: HCV genotype (Gt), Fib-4 score, length of therapy (LOT), HIV viral load (VL), CD4+ cell count, antiretroviral therapy (ART), HCV RNA levels at baseline, 4 weeks, 8 weeks, end of therapy (EOT), and SVR at week 12 post-treatment. Statistical analysis was performed using Stata version 14 (STATA Corp., Texas, USA).
Results. A total of 94 patients were included. The mean age was 54 years-old, 78% were male. Most patients (95%) had Gt 1 HCV infection (84% 1A, 11% 1B and 1% mixed), 4% Gt 4, and one patient had Gt 6; 24% of patients had compensated cirrhosis.
Median LOT was 12 weeks. 95% of patients received 12 weeks, 4% 24 weeks, and 1% received 16 weeks of therapy. Most patients had undetectable HIV VL (77% with <20 copies/mL), while 23% had HIV VL range from 20 to 1,430 copies/mL. The mean CD4+ count was 639 cells/microliters (95% CI 567-711). The most commonly used ARTs were efavirenz/emtricitabine/tenofovir (21%), followed by abacavir/dolutegravir/lamivudine (15%). SVR12 was achieved in 99% (93/94) of patients (100% in HCV treatment experienced). Of those patients, 86/91 achieved HCV VL <15 at week 4 and 80/82 at EOT. The mean Fib-4 score at start of therapy was 2.33 with post-therapy of 1.35. One patient (Gt 1A, F4, on FTC/TDF/RAL) failed therapy secondary to NS5a mutation (L31M/V) and was retreated with sofosubuvir/simeprevir for 12 weeks achieving SVR 12. Interestingly, 4 patients had undetectable HCV VL at EOT with post-EOT HCV viremia (157-4511 IU/mL) that resolved on its own on repeated testing.
Conclusion. Our HCV real-life experience with ledipasvir/sofosbuvir at a freestanding HIV clinic confirms the efficacy and safety reported in randomized clinical trials. NS5A mutation led to treatment failure in this heterogeneous group of patients.
Disclosures. Saturday, October 7, 2017: 12:30 PM Background. Societal and economic burdens of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) continue to grow. The CDC recommends a one-time HCV screen for individuals in the Baby Boomer population (those born between 1945 and 1965) and a one-time HIV screen for all individuals between ages 13-64, with more frequent screening for both conditions based on individual risk factors.
Methods. A system-wide electronic medical record alert prompting HCV screening was implemented in May 2016 targeting the Baby Boomer population. In addition to the system alert, an educational program detailing disease epidemiology, screening recommendations, and algorithms to guide screening efforts was developed by a quality improvement team to increase HCV and HIV screening and linkage to care for positive patients. Carolinas HealthCare System (CHS) is a nonprofit, vertically integrated healthcare system with approximately 12 million patient encounters per year. Twelve primary care practices, including 5 safety-net practices serving predominantly Medicaid and uninsured patients, with total of 43,000 patients born between 1945 and 1965 were selected for the educational intervention.
Results. Prior to the system-wide HCV alert, from May-December 2015, 2430 patients were screened for Hepatitis C; one year later post-HCV alert, from MayDecember 2016, 8872 patients were screened, resulting in a 350% increase in screening. Chi-squared analysis comparing the percentage of patients tested between the two-time periods was significantly different (P = 0.001). For the educational intervention initiated in November 2016: average patient HCV testing over the 12 sites was 1480 per month before the intervention, and rose to 1713 per month post-education implementation (P < 0.001). Similarly, for HIV testing: average patient HIV testing was on average 493 per month increasing to 621 average per month after the educational program (P < 0.001) Conclusion. EMR modifications and provider education along with availability of connect to care partners within a large, integrated, healthcare system can significantly enhance screening and care for patients with HCV and HIV. Innovative interventions are needed to improve screening rates and link positive patients into care.
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Session: 245. HIV and HCV Saturday, October 7, 2017: 12:30 PM Background. Viral hepatitis is common among individuals who attend narcotic replacement therapy (NRT) programs, yet screening is not universally implemented. Programs may use behavioral risk questionnaires to determine whom to screen, though the efficacy of this approach has not been assessed. We compared risk score from the behavioral risk intake assessments at our institution's NRT program with the results of HIV and viral hepatitis tests, and analyzed the care continuum for HCVdiagnosed NRT participants.
Methods. Retrospective chart review of NRT participants. All charts were reviewed for high-risk or risk-not-assessed individuals and a random subset of charts were reviewed for individuals determined to have medium or low risk. Intake viral screening, subsequent testing during NRT participation, evaluation and linkage to care for HCV, HBV and HIV were collected. Data was extrapolated to estimate baseline screening, prevalence and care continuum data among all NRT participants.
Results. As of October 2016, 866 individuals were enrolled in NRT. 27% of the charts reviewed had full HIV/HCV/HBV screening completed at intake. Overall, 33% of individuals were tested for HIV and 1 individual tested positive; 46% of individuals were tested for HBV and 1 individual tested positive; and 47% were tested for HCV Ab, of which 37% tested positive. By risk behavior questionnaires, 4% of individuals were considered high risk for viral infection, 54% medium risk, 34% low risk, and 8% not assessed. See Figure 1 . The percentage of positive HCV tests was high across all risk groups (26%-58%). 150 individuals in the entire cohort were estimated to have been diagnosed HCV RNA+ (37% of those tested, 14% of all participants); 7 were treated and cured (6% of those RNA+). See Figure 2 .
Conclusion. Participants in the NRT program had low rates of HIV and HBV and high rates of HCV exposure across all behavioral risk levels. 14% of the cohort were diagnosed with active HCV, though fewer than half of the participants were tested. HCV referral, linkage and treatment rates were low across all subgroups; interventions to expand testing to all intakes regardless of risk score and optimize linkage to care could greatly impact diagnosis and treatment rates among this high-prevalence population. Saturday, October 7, 2017: 12:30 PM Background. The use of contraception for family planning is critically important for women living with HIV (WLH), but barriers to co-use of hormonal contraceptives (HC) and antiretroviral therapy (ART) exist due to drug-drug interaction (DDI) potential. The objective of this study was to describe the type and frequency of HC and ART used among WLH and to identify the prevalence and severity of DDI potential between HC and ART.
Disclosures. All authors: No reported disclosures.

Prevalence of Drug-Drug Interactions with Hormonal Contraceptives and Antiretrovirals in Women Living with HIV
Methods. This was a retrospective chart review of WLH, receiving ART, who were 18-60 years old, and had at least one clinic visit at the Northwestern Infectious Disease Center from January 1, 2010 to April 30, 2014. Electronic medical charts were reviewed to assess demographics and history of contraceptive and ART use. For each combined HC and ART regimen, DDI potential and severity (major, moderate or minor) was assessed using the University of Liverpool HIV Drug Interactions website (www.hiv-druginteractions.org).
Results. During the study period, 317 women had a median of 8 clinic visits (interquartile range (IQR) 5-13) and received a total of 438 ART regimens: ritonavir-boosted PI-(282, 64.4%), NNRTI-(80, 18.3%), other-(45, 10.3%), INSTI-based (31, 7.1%). The cohort had a median age of 37 years (IQR 28-46); 170 (54.3%) were African American and 277 (88.5%) were non-Hispanic. The use of any contraceptive method was reported in 169 (53.3%) women, of which 75 (44.4%) reported using HC, mostly commonly a progestin intrauterine device (43, 57.3%) or injection (17, 22.7%), or combination oral contraceptive pill (OCP; 9, 12%). A potential DDI (all moderate severity) was identified in 74 of 113 ART-HC-regimen combinations, representing 57 (76%) women using ART and HC. Ritonavir-boosted PIs were the ART most frequently implicated in a potential DDI (62, 83.8%); for HC, this was the progestin intrauterine device (51, 68.9%) and OCP (17, 23%).
Conclusion. Approximately one-third of WLH using any contraceptive in our clinic had a potential DDI with ART. Though frequently used and implicated, the progestin IUD is unlikely to result in a clinically significant DDI with ART, but confirmation of this assumption is warranted. Relative to its frequency of use, there was high prevalence of potential OCP-ART DDI; the clinical implications need to be further explored.
Disclosures. All authors: No reported disclosures. Saturday, October 7, 2017: 12:30 PM Background. During late pregnancy, the standard dose of atazanavir boosted with ritonavir (ATV/r) is increased to 400/100mg once daily and the standard dose of lopinavir boosted with ritonavir (LPV/r) is increased to 600/150mg twice daily due to physiologic and metabolic changes. These higher doses may impact the tolerability of antiretroviral therapy (ART). The objective of this study was to describe adverse events (AE) in pregnant women living with HIV receiving ATV/r vs. LPV/r.
Safety and Tolerability of High Dose Atazanavir-Ritonavir and LopinavirRitonavir in Pregnant Women
Methods. This retrospective cohort included pregnant women receiving high dose ATV/r or LPV/r-based ART from Sept 2007-Dec 2014. AEs were assessed by laboratory parameters and medical chart documentation from the first visit during pregnancy through delivery. AE severity was based on the Division of AIDS Table for Grading the Severity of Adult AEs. The primary endpoint was a between-group comparison of documented AEs. Data are presented as n, percent, or median (interquartile range, IQR).
Results. A total of 99 patients were included (n = 41 ATV/r, n = 58 LPV/r). Patients were 29 years old (IQR 24-34), African American (43%), and living with HIV for 5 years (IQR 1-9). Baseline demographics were similar between groups. Overall, 94.8% of the LPV/r arm experienced at least one AE (n = 58), and 70.7% (n = 29) experienced an AE in the ATV/r arm (P < 0.01). There were 3.8 AEs/patient (n = 218) in the LPV/r arm and 2.6 AEs/patient (n = 106) in the ATV/r arm. Nausea/vomiting was the most common AE in each arm (n = 44 LPV/r and n = 19 ATV/r). Most AEs were grade 1 in (LPV/r: 194 (89%) and ATV/r: 81 (76%); P < 0.01); however, there were a higher number of grade 3 (n = 7 ATV/r, n = 5 LPV/r) and grade 4 (n = 2 ATV/r, n = 0 LPV/r) AEs seen in the ATV/r arm. LPV/r was discontinued in 3 patients and ATV/r was discontinued in 2 patients. There was no difference in percentage of patients with an undetectable viral load at any monitoring point including the week before end of term (n = 29/32, 90.6% ATV/r; n = 33/42, 78.6% LPV/r; P > 0.05 for all).
Conclusion. Patients treated with ATV/r experienced lower overall rates of AEs compared with LPV/r. The majority of AEs were grade 1 and few patients needed to discontinue ATV/r or LPV/r due to AEs.
Comparison of Two Antiretroviral Therapy Regimens in Human Immunodeficiency Virus (HIV−) Infected Pregnant Women
